港股异动 | 加科思-B(01167)午后涨逾23% 治疗实体瘤新药临床实验申请近日在美国获批
加科思-B(01167)午后涨逾23%。截至发稿，涨19.51%，报1.96港元，成交额1153.26万港元。
消息面上，加科思此前公布，其自主研发的P53 Y220C激活剂JAB-30300的新药临床试验申请(IND)，已获得美国食品药监局(FDA)批准。据悉，目前P53 Y220C激活剂在全球只有一个同类项目处于临床一期。JAB-30300有望成为首批上市的产品之一。
此外，加科思药业于2月中旬公布，其自主研发的SHP2抑制剂JAB-3312与KRAS G12C戈来雷塞抑制剂联用在中国获批开展三期临床试验。这一事件标志着SHP2这个还未成药的靶点正式进入三期临床试验，距离获批上市迈出关键一步。
Reprinted from 引领外汇网，the copyright all reserved by the original author.
Disclaimer: The content above represents only the views of the author or guest. It does not represent any views or positions of FOLLOWME and does not mean that FOLLOWME agrees with its statement or description, nor does it constitute any investment advice. For all actions taken by visitors based on information provided by the FOLLOWME community, the community does not assume any form of liability unless otherwise expressly promised in writing.
FOLLOWME Trading Community Website: https://www.followme.com
Hot
No comment on record. Start new comment.